Nuwellis, Inc. (NUWE) Stock Price & Analysis
Nuwellis, Inc. (NUWE) rose 0.14% to USD 0.15 as of June 10, 2026 at 05:02 UTC, according to Nexqual real-time market data.
NUWE last closed at USD 0.15; the session ranged USD 0.14–0.15 on volume of 4,599,235 shares. Market capitalization is $703,550, with a 52-week range of USD 0.13–25.95 (NCM). Source: Nexqual, June 10, 2026 at 05:02 UTC.
Key Statistics (as of June 10, 2026 at 05:02 UTC)
| Price | USD 0.15 |
|---|---|
| Change | ▲ 0.14% (up) |
| Previous Close | USD 0.15 |
| Open | USD 0.14 |
| Day Range | USD 0.14 – 0.15 |
| 52-Week Range | USD 0.13 – 25.95 |
| Volume | 4,599,235 shares |
| Market Cap | $703,550 |
| Exchange | NCM |
Technical Analysis (NUWE)
Nexqual's technical model rates NUWE "SELL" based on 3 bullish and 5 bearish signals across 123 daily candles, as of June 10, 2026 at 05:02 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 12.53 (oversold) |
| vs SMA50 | Below (USD 0.99) |
| MACD | -0.21 (negative) |
Analyst Ratings (NUWE)
Wall Street analysts rate NUWE "None", per Nexqual as of June 10, 2026 at 05:02 UTC.
| Consensus Rating | None |
|---|---|
| Buy / Hold / Sell | 0 / 1 / 0 |
Earnings (NUWE)
| Next Earnings Date | 2026-08-13 |
|---|---|
| Revenue Estimate | $2.42M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2025-12-31 | USD -1.5 vs est -1.56 ▲ beat |
Source: Nexqual, June 10, 2026 at 05:02 UTC.
Financials & Fundamentals (NUWE)
| Total Revenue | $8.77M |
|---|---|
| Revenue Growth (YoY) | +26.20% |
| Gross Margin | +65.47% |
| Operating Margin | -181.65% |
| Profit Margin | -214.91% |
| ROE | -583.80% |
| Debt / Equity | 9.22 |
| Current Ratio | 1.56 |
| Total Cash | $2.08M |
| Total Debt | $265,000 |
| Free Cash Flow | $-13.27M |
Source: Nexqual, June 10, 2026 at 05:02 UTC.
Financial Health Score (NUWE)
Nexqual rates Nuwellis, Inc.'s overall financial health "Weak" across five dimensions, as of June 10, 2026 at 05:02 UTC.
| Growth | Weak — Revenue -5% YoY (annual), declining |
|---|---|
| Profitability | Critical — Heavily loss-making — early-stage company |
| Balance Sheet | Strong — $2M cash, no debt |
| Cash Flow | Weak — FCF negative: -$13M, burning cash |
| Efficiency | Critical — ROE -584%, ROA -109.5% |
Ownership (NUWE)
| Insider Ownership | +1.03% |
|---|---|
| Institutional Ownership | +11.06% |
| Shares Outstanding | 4.85M |
| Float | 2.61M |
| Short % of Float | +12.67% |
Source: Nexqual, June 10, 2026 at 05:02 UTC.
Leadership (NUWE)
Nuwellis, Inc. is led by John L. Erb (age 76), CEO, President & Chairman, per Nexqual as of June 10, 2026 at 05:02 UTC.
| CEO, President & Chairman | John L. Erb (age 76) |
|---|---|
| CFO, Principal Financial Officer & Principal Accounting Officer | Carisa Schultz (age 47) |
| Vice President of Operations | Kim Anderson |
| Chief Technology Officer | David Lerner |
| Director of Communications | Leah McMullen |
Major Backers & Investors (NUWE)
Notable institutional backers of Nuwellis, Inc. include Armistice Capital, LLC, Fidelity, Citigroup Inc., according to Nexqual as of June 10, 2026 at 05:02 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Armistice Capital, LLC | 8.81% |
| Fidelity | 1.62% |
| Citigroup Inc. | 0.19% |
| Tower Research Capital LLC (TRC) | 0.19% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Geode Capital | 1.65% |
Source: Nexqual, June 10, 2026 at 05:02 UTC.
From Nuwellis, Inc.'s Latest SEC 10-K Filing (filed 2026-03-11)
Key Strengths & Strategy (as disclosed to the SEC)
- Food and Drug Administration ("FDA") to support its use in the applications identified immediately above.   The Company believes the total U.S. critical care failure market is approximately $900 million. 6 5 In 2025, the Company derived approximately 32% of its revenue from the treatment of critical care patients.   56  https://idataresearch.com/new-study-shows-approximately-340000-cabg-procedures-per-year-in-the-united-states/. 57  Kruger A et al.
- The company is focused on developing, manufacturing, and commercializing medical devices used in ultrafiltration therapy, including the Aquadex FlexFlow® and the Aquadex SmartFlow® systems (collectively the "Aquadex System").
- With our FDA 510(k) clearance for use in pediatric patients weighing 20kg or more, we have expanded our commercialization efforts to treatments for pediatric patients.   Critical Care : We have launched a marketing campaign focused on the benefits of the Aquadex System in treating patients suffering from fluid overload following cardiac surgery procedures, such as CABG surgery, valve repairs and replacements procedures, VAD implants and other cardiac surgical procedures.
- In February 2020, the Company received FDA 510(k) clearance for the Aquadex System to include pediatric patients who weigh 20kg or more.
Partnerships
- We purchased parts and components for the Aquadex System from third-party manufacturers and suppliers.   19 Table of Contents On May 12, 2025, the Company announced it had finalized an agreement with KDI Precision Manufacturing to support the next phase of Nuwellis' growth.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| ENSC | Ensysce Biosciences, Inc. | USD 0.25 | ▲ 0% |
| SHPH | Shuttle Pharmaceuticals Holding | USD 0.45 | ▼ 0.33% |
| QNRX | Quoin Pharmaceuticals, Ltd. | USD 4.95 | ▲ 10.24% |
| REVB | Revelation Biosciences, Inc. | USD 1.04 | ▲ 5.05% |
| PALI | Palisade Bio, Inc. | USD 1.69 | ▼ 2.87% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 05:02 UTC. This page is informational and not investment advice.